Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)

Mohsen Sadatsafavi; Ruth B Murray; Nasloon  Ali; Trung N Tran; David Price; ISAR FIRE Working Group

Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)

Mohsen Sadatsafavi, Ruth B Murray, Nasloon Ali, Trung N Tran, David Price, ISAR FIRE Working Group

Research output: Contribution to conference › Abstract › peer-review

4 Downloads (Pure)

Abstract

Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R therapy. However, it is not clear whether one class of biologic works better than the other amongst patients eligible for both.

Original language	English
Publication status	Accepted/In press - 12 Mar 2021
Event	ATS International Conference Committee: ATS 2021 - Virtual event Duration: 14 May 2021 → 19 May 2021 https://conference.thoracic.org/

Conference

Conference	ATS International Conference Committee
Period	14/05/21 → 19/05/21
Internet address	https://conference.thoracic.org/

Access to Document

Sadastsafavi_et_al_ATS_WorldwideCharacterizationOfSevereAsthma_AAM
Originally Published in: [Authors]. [Article Title]. [Journal Name] [Year];[Volume]:[Pages]. DOI: [Number] Copyright ©2021 by the American Thoracic Society The final publication is available at [Link].
Accepted author manuscript, 425 KBLicence: Other

Fingerprint Dive into the research topics of 'Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)'. Together they form a unique fingerprint.

Cite this

Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy : data from the International Severe Asthma Registry (ISAR). / Sadatsafavi, Mohsen; Murray, Ruth B; Ali, Nasloon ; Tran, Trung N; Price, David; ISAR FIRE Working Group.

2021. Abstract from ATS International Conference Committee, .

Research output: Contribution to conference › Abstract › peer-review

@conference{2e6dbebdb338444d9d8fc2f3e215da4f,

title = "Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)",

abstract = "Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R therapy. However, it is not clear whether one class of biologic works better than the other amongst patients eligible for both.",

author = "Mohsen Sadatsafavi and Murray, {Ruth B} and Nasloon Ali and Tran, {Trung N} and David Price and {ISAR FIRE Working Group}",

note = "Funding: ISAR is conducted by OPC Global, and co-funded by OPC Global and AstraZeneca.; ATS International Conference Committee : ATS 2021 ; Conference date: 14-05-2021 Through 19-05-2021",

year = "2021",

month = mar,

day = "12",

language = "English",

url = "https://conference.thoracic.org/",

}

TY - CONF

T1 - Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy

T2 - ATS International Conference Committee

AU - Sadatsafavi, Mohsen

AU - Murray, Ruth B

AU - Ali, Nasloon

AU - Tran, Trung N

AU - Price, David

AU - ISAR FIRE Working Group

N1 - Funding: ISAR is conducted by OPC Global, and co-funded by OPC Global and AstraZeneca.

PY - 2021/3/12

Y1 - 2021/3/12

N2 - Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R therapy. However, it is not clear whether one class of biologic works better than the other amongst patients eligible for both.

AB - Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R therapy. However, it is not clear whether one class of biologic works better than the other amongst patients eligible for both.

M3 - Abstract

Y2 - 14 May 2021 through 19 May 2021

ER -